Shearlink Capital Has Cut By $5.13 Million Its Salesforce Com (CRM) Holding; Shorts at Dicerna Pharmaceuticals (DRNA) Lowered By 9.84%

December 7, 2017 - By Vivian Currie

Shearlink Capital Llc decreased Salesforce Com Inc (CRM) stake by 52.7% reported in 2017Q2 SEC filing. Shearlink Capital Llc sold 59,612 shares as Salesforce Com Inc (CRM)’s stock rose 7.28%. The Shearlink Capital Llc holds 53,500 shares with $4.63M value, down from 113,112 last quarter. Salesforce Com Inc now has $75.17B valuation. The stock increased 1.12% or $1.15 during the last trading session, reaching $104.07. About 3.82M shares traded., inc. (NYSE:CRM) has risen 7.78% since December 7, 2016 and is uptrending. It has underperformed by 8.92% the S&P500.

Dicerna Pharmaceuticals Incorporated (NASDAQ:DRNA) had a decrease of 9.84% in short interest. DRNA’s SI was 379,500 shares in December as released by FINRA. Its down 9.84% from 420,900 shares previously. With 71,800 avg volume, 5 days are for Dicerna Pharmaceuticals Incorporated (NASDAQ:DRNA)’s short sellers to cover DRNA’s short positions. The SI to Dicerna Pharmaceuticals Incorporated’s float is 3.03%. The stock decreased 3.78% or $0.3 during the last trading session, reaching $7.64. About 300,229 shares traded or 8.86% up from the average. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has declined 5.22% since December 7, 2016 and is downtrending. It has underperformed by 21.92% the S&P500.

Among 5 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dicerna Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. Stifel Nicolaus maintained the shares of DRNA in report on Thursday, June 30 with “Buy” rating. Chardan Capital Markets maintained the shares of DRNA in report on Monday, August 15 with “Neutral” rating. Stifel Nicolaus maintained the shares of DRNA in report on Monday, August 10 with “Buy” rating. The firm earned “Buy” rating on Tuesday, May 10 by Stifel Nicolaus. Chardan Capital Markets maintained Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) rating on Thursday, June 30. Chardan Capital Markets has “Neutral” rating and $4 target. Cowen & Co maintained the stock with “Buy” rating in Wednesday, August 16 report. Leerink Swann reinitiated the stock with “Mkt Perform” rating in Tuesday, January 31 report. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Stifel Nicolaus on Wednesday, November 11. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, November 2. Cowen & Co maintained the stock with “Buy” rating in Tuesday, July 18 report.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $159.28 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

Investors sentiment decreased to 0.55 in 2017 Q2. Its down 0.40, from 0.95 in 2017Q1. It worsened, as 9 investors sold Dicerna Pharmaceuticals, Inc. shares while 11 reduced holdings. 4 funds opened positions while 7 raised stakes. 11.04 million shares or 3.09% more from 10.71 million shares in 2017Q1 were reported. Northern Tru Corp holds 36,219 shares. Birchview Capital Lp has 20,000 shares. Massachusetts-based Panagora Asset Mngmt Incorporated has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Bank Of America De owns 35 shares for 0% of their portfolio. Fmr Limited Liability Com holds 0% or 2.35M shares in its portfolio. Blackrock accumulated 0% or 115,065 shares. Sabby Management Limited Liability has invested 0.04% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Wells Fargo Mn stated it has 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). California Employees Retirement Systems holds 0% or 41,000 shares in its portfolio. 683 Mgmt Ltd Liability Com reported 0.37% stake. Creative Planning owns 7,611 shares for 0% of their portfolio. Connor Clark Lunn Invest Mngmt invested in 0% or 79,275 shares. Qs Investors Limited Liability holds 0% or 1,071 shares in its portfolio. Paloma Prtnrs Co owns 160,000 shares. Eventide Asset Limited Liability Company holds 0.07% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) or 377,000 shares.

Since June 8, 2017, it had 0 insider purchases, and 9 sales for $6.88 million activity. Benioff Marc sold $1.74M worth of stock or 20,000 shares. Roos John Victor had sold 228 shares worth $19,606 on Thursday, June 15. 10,000 shares were sold by BLOCK KEITH, worth $878,671 on Tuesday, June 13. $85,990 worth of, inc. (NYSE:CRM) was sold by Conway Craig. Shares for $700,850 were sold by Harris Parker on Tuesday, June 13.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :